A Phase 1b, Open-Label, 2-part, Safety, Tolerability, and Efficacy Study of a Soluble Beta-Glucan (Odetiglucan) in Combination with a CD40 Agonistic Monoclonal Antibody (CDX-1140) in Patients with Metastatic Pancreatic Adenocarcinoma Whose Disease Did Not Progress During First-Line (1L) Chemotherapy